Genetic engineering market seen reaching $20.57B by 2032

The global genetic engineering market is projected to surge from $1.62 billion in 2025 to $20.57 billion by 2032, driven by gene-editing adoption, personalized medicine and biotech investment. The report points to CRISPR, synthetic biology and healthcare applications as the biggest growth engines, with North America leading and Asia-Pacific growing fastest.

Why it matters: - The genetic engineering market is projected to expand rapidly as gene editing, personalized medicine and advanced diagnostics move deeper into healthcare. - The market is also becoming more important for agriculture, industrial biotechnology and environmental applications. - The scale of the forecast signals growing commercial demand for technologies that can change how diseases, crops and biological manufacturing are handled.

What happened: - The global genetic engineering market was valued at $1.62 billion in 2025. - The market is projected to reach $20.57 billion by 2032. - The forecast implies a 20.9% compound annual growth rate during the period. - Maximize Market Research published the outlook on June 10, 2026. - Get a sample of the report.

The details: - Genetic engineering is being used to modify genetic material for healthcare, agriculture, industrial biotechnology and environmental science. - Healthcare uses include targeted therapies, gene therapies and advanced diagnostics. - The technology has changed treatment approaches for inherited diseases, cancer and rare genetic disorders. - Agricultural demand is rising for genetically modified crops with higher yields, pest resistance and climate resilience. - Increasing prevalence of genetic disorders and chronic diseases is a major market driver. - Gene-editing trials and regulatory approvals for genetic medicines are strengthening investor confidence. - CRISPR and other genome-editing tools are improving precision, efficiency and cost. - Declining sequencing and analysis costs are broadening use cases. - Government biotechnology support, plus public and private funding, is adding momentum. - Strategic collaborations among pharmaceutical companies, research institutes and biotech firms are accelerating product development. - CRISPR-Cas systems dominate the technology mix because of their efficiency, precision and cost-effectiveness. - Synthetic biology is gaining momentum as companies seek customized biological systems. - Healthcare and therapeutics hold the largest application share, driven by gene therapies, personalized medicine and diagnostics. - Biotechnology companies and pharmaceutical companies remain the leading end users. - North America leads the market because of biotechnology infrastructure, research funding and favorable regulation. - Asia-Pacific is expected to grow fastest on the back of life sciences investment, healthcare expansion and rising research activity. - A sample request and the full report are available through Maximize Market Research’s website via the links provided.

Between the lines: - The report frames genetic engineering as a platform technology rather than a single product category. - That matters because demand can compound across healthcare, agriculture and manufacturing at the same time. - The strongest near-term growth appears tied to precision medicine and gene therapies, while longer-term upside depends on synthetic biology and industrial use cases. - AI and machine learning are becoming part of genomic research workflows, which could speed target discovery and editing design. - Base editing, prime editing and epigenome editing suggest the field is moving beyond first-generation CRISPR applications.

What’s next: - Researchers are expected to keep pushing CRISPR-based therapies into cancer, neurological disease and cardiovascular disease studies. - Drug developers and biotech firms are likely to keep investing in next-generation gene-editing platforms with lower off-target effects. - Agricultural developers are expected to expand work on drought tolerance, nutrition improvement and pesticide reduction. - Delivery systems such as viral vectors, lipid nanoparticles and non-viral platforms should remain a focus as gene therapy programs scale. - The market outlook depends on continued regulatory progress, broader clinical adoption and further convergence with synthetic biology and AI.

The bottom line: - Genetic engineering is moving from a specialized research field to a core growth market for medicine, food and bio-manufacturing.